HCM - Hutchmed Roils Markets With Changing Of Its Guard U.S. Delisting Threat
- U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO.
- Company’s shares have tumbled more than 40% on the developments, even as it reported strong revenue gains for 2021 and nears its first approval to sell a drug in the U.S.
- Hutchmed’s Hong Kong-listed shares were down nearly 16% in early Friday trade, amid a broader selloff for the many Chinese companies that could also be affected.
For further details see:
Hutchmed Roils Markets With Changing Of Its Guard, U.S. Delisting Threat